The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

Bin Yu; Jin Zhou; Hongzhou Cai; Ting Xu; Zicheng Xu; Qing Zou; Min Gu ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...